A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

NCT03755102 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

EGFR Gene Mutation
Lung Cancer
Lung Cancer Metastatic

Interventions

DRUG: Dacomitinib
DRUG: Osimertinib

Sponsor

Memorial Sloan Kettering Cancer Center